Lung cancer DNA vaccine - Immune Cell Therapy

Drug Profile

Lung cancer DNA vaccine - Immune Cell Therapy

Alternative Names: IC-1001; IC-1001 personalised lung cancer vaccine; IC-1001 personalized lung cancer vaccine

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator Immune Cell Therapy
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 04 Apr 2016 No development reported - Phase-I for Non-small cell lung cancer in USA (Intradermal)
  • 31 Jan 2012 Phase-I clinical trials in Non-small cell lung cancer in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top